Abstract
Real world data for second (2nd) line treatment and effectiveness depending on HER2 expression in gastric cancer are lacking. The objectives of this analysis were to evaluate 2nd line treatments effectiveness, and to explore HER2 expression potential effect on paclitaxel + ramucirumab (RAMUPACLI).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
